SAFETY OF CONTINUOUS NEBULIZED ALBUTEROL FOR BRONCHOSPASM IN INFANTS AND CHILDREN

Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for broncho spasm. Design. Prospective, case series. Setting. A university pediatr ic intensive care and pediatric subacute units. Patients. Nineteen inf ants and children who received CNA for at least 24 hours. Intervention s. None. Measurements. Creatinine phosphokinase (CK) was measured at t he time of admission and then at 12, 24, 48, and 72 hours while the pa tient received CNA. Isoenzyme CK-MB fractions were measured if CK conc entration was greater-than-or-equal-to 250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy. Main results. Creatinine phosphokinase levels remained within normal l imits for 16 patients during CNA treatment. Three patients had elevate d CK and in two CK-MB fractions were elevated at one measurement. None of the electrocardiograms showed evidence of ischemia and no arrhythm ias were noted during CNA therapy, even in the patients with elevated CK-MB fractions. Conclusions. Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK- MB without other evidence of cardiotoxicity remains to be determined.